

For chronic weight management in adults with a BMI of ≥ 30 kg/m² (obesity), or ≥ 27 kg/m² (overweight) in the presence of a weight-related comorbidity, as an adjunct to a reduced calorie diet and increased physical activity.



ONCE - WEEKLY

wegovy™

semaglutide injection 2.4 mg

[Click here to see the Prescribing Information, including Boxed Warning](#)

Indications and Usage

Wegovy™ (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Limitations of Use

- Wegovy™ contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist.
- The safety and effectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
- Wegovy™ has not been studied in patients with a history of pancreatitis.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- **In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.**
- **Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy™ and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy™.**

Contraindications

- Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide.

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart.
- **Acute Gallbladder Disease:** In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
- **Hypoglycemia:** Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased

risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes.

- **Acute Kidney Injury:** There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion.
- **Hypersensitivity:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
- **Diabetic Retinopathy Complications in Patients with Type 2 Diabetes:** In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
- **Heart Rate Increase:** Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™.
- **Suicidal Behavior and Ideation:** Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation.

Adverse Reactions

- The most common adverse reactions reported in $\geq 5\%$ of patients treated with Wegovy™ are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.

Drug Interactions

- The addition of Wegovy™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
- Wegovy™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy™.

Use in Specific Populations

- **Pregnancy:** May cause fetal harm. When pregnancy is recognized, discontinue Wegovy™. Discontinue Wegovy™ in patients at least 2 months before a planned pregnancy.

[Click here to see the Prescribing Information, including Boxed Warning.](#)


Wegovy™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US21SEM000380 June 2021



BRIEF CUTTING EDGE REPORT

Epidemiology/Genetics

Microvascular Differences in Individuals With Obesity At Risk of Developing Cardiovascular Disease

Anouk I. M. van der Velden¹ | Bernard M. van den Berg¹  | Renée de Mutsert² | Johan van der Vlag³ | J. Wouter Jukema⁴ | Frits R. Rosendaal² | Ton J. Rabelink¹ | Hans Vink⁵

¹Division of Nephrology, Department of Internal Medicine, The Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands

²Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

³Department of Nephrology, Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

⁴Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

⁵Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands

Correspondence

Anouk I. M. van der Velden, Department of Internal Medicine C7-Q-36, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
Email: a.i.m.van_der_velden@lumc.nl

Funding information

This study was supported by a grant (LSHM16058-SGF) for the GLYCOTREAT consortium, a collaboration project financed by the public-private partnership (PPP) allowance made available by Top Sector Life Sciences & Health to the Dutch Kidney Foundation to stimulate public-private partnerships. The Netherlands Epidemiology of Obesity (NEO) study is supported by participating departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University Research Profile Area "Vascular and Regenerative Medicine." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

Objective: This study aimed to investigate microvascular differences in individuals with obesity at risk for developing cardiovascular disease.

Methods: In this cross-sectional Netherlands Epidemiology of Obesity study, participant sublingual microcirculation was assessed with a newly developed GlycoCheck software (Microvascular Health Solutions Inc., Salt Lake City, Utah), which integrates red blood cell velocity within the smallest capillaries (4-7 μm) and feed vessels (>10 μm). Framingham Risk Score was used to calculate 10-year cardiovascular risk, divided into low-, intermediate-, and high-risk groups. ANOVA was used to evaluate microvascular differences among the groups.

Results: A total of 813 participants were included. The high-risk group ($n = 168$) was characterized by differences in the microvasculature compared with the low-risk group ($n = 392$): the high-risk group had a 49% reduction in the number of smallest capillaries and a 9.1- $\mu\text{m}/\text{s}$ (95% CI: 5.2-12.9) higher red blood cell velocity in the feed vessels. No differences in velocity-corrected perfused boundary regions were found.

Conclusions: It was observed that, with adding red blood cell velocity to the software, sidestream dark field imaging is able to detect microcirculatory differences in a cohort of individuals with obesity at risk for developing cardiovascular disease.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *Obesity* published by Wiley Periodicals LLC on behalf of The Obesity Society (TOS).

INTRODUCTION

Obesity is a well-established risk factor for developing cardiovascular disease (CVD), the leading cause of mortality worldwide. One of the earliest changes in CVD pathogenesis is microvascular endothelial dysfunction (1,2). Recently, we showed that, early in diabetes, the endothelial glycocalyx is perturbed, which results in reduced tissue perfusion and decreased perfused capillary density (3,4). Detecting early microvascular changes, long before the onset of clinical symptoms of CVD, and monitoring the response of therapeutic interventions may improve cardiovascular outcome. However, techniques to easily assess the dynamic microcirculation in humans are limited (5,6).

Subsequent to our previous sidestream dark field (SDF) imaging analysis in a subpopulation of the Netherlands Epidemiology of Obesity (NEO) study (7), we present a newly developed software application that facilitates automatic analysis of red blood cell (RBC) velocity, allowing us to include flow changes between feed vessels and capillaries to be coupled to perfused boundary region (PBR) and perfused capillary density measurements. In the current study, we reanalyzed our previous SDF measurements and divided the cohort into cardiovascular risk groups according to Framingham Risk Score. The Framingham Risk Score is a sex-specific algorithm that is widely used to assess the risk of cardiovascular events (coronary, cerebrovascular, and peripheral artery disease and heart failure) within 10 years.

Because microvascular dysfunction is one of the first signs of CVD, we aimed to investigate whether individuals with obesity and a high risk for developing CVD could be characterized by microvascular changes measured with SDF imaging.

METHODS

Study design and population

The population-based prospective-cohort NEO study, designed to investigate pathways leading to obesity-related diseases, started in 2008 and included 6,671 individuals aged 45 to 65 years, with an oversampling of individuals with overweight (BMI of 27 kg/m² or higher). Detailed information about the NEO study design and data collection is described elsewhere (7). The Medical Ethical Committee of the Leiden University Medical Center approved the design of the study. All participants gave their written informed consent.

The present study included 918 participants in whom SDF imaging was performed between January and October 2012 as part of the baseline visit at the Leiden University Medical Center NEO study center.

Framingham Risk Score

The Framingham Risk Score was used to calculate the risk of general CVD by using the risk factors gender, age, total and high-density

Study Importance

What is already known?

- Microvascular changes due to endothelial dysfunction is an early step in the pathogenesis of cardiovascular disease. Sidestream dark field imaging is a noninvasive technique to detect these microvascular changes.

What does this study add?

- By analyzing densities of blood perfused microvessels in a diameter-dependent manner, it is demonstrated that significant reductions in the number of the smallest capillaries can be identified in individuals with obesity exposed to increased cardiovascular risk according to the Framingham Risk Score. This new analysis could be used for early detection of microvascular changes in individuals with obesity that might aid in monitoring such individuals, e.g., using various interventions.

How might your results change the direction of research or the focus of clinical practice?

- By adding red blood cell velocity calculations to the new sidestream dark field imaging software, a better estimate of perfused boundary regions can be implemented that can be used to detect early signs of microvascular damage. Automated imaging can be used to detect early microvascular changes and monitor clinical interventions aimed at restoring microvascular health.

lipoprotein cholesterol, systolic blood pressure, treatment for hypertension, current smoking, and diabetes status. The Framingham Risk Score was reported as absolute risk percentage classified as low (<10%), intermediate (10%-20%), or high (>20%) 10-year predicted risk of CVD (8).

SDF microcirculation imaging

Intravital microscopy was performed earlier using an SDF camera (MicroVision Medical Inc., Wallingford, Pennsylvania) and acquired using Glycocheck software (Microvascular Health Solutions Inc., Salt Lake City, Utah) as described elsewhere (5).

The new software includes RBC velocity as a new parameter. After reanalyzing, the following parameters were obtained: perfused capillary density, absolute and static capillary blood volume, RBC velocity, and static and dynamic PBR. Detailed information about the new software used in the NEO study is described elsewhere (5,9)

TABLE 1 Characteristics and SDF-derived parameters of the study population stratified by Framingham Risk Score group and total cohort

	Low risk (n = 392)	Intermediate risk (n = 253)	High risk (n = 168)	Total cohort (n = 813)
Demographics				
Age (y)	54 (6)	57 (6)	60 (5)	56 (6)
Women (%)	81	37	12	53
Postmenopausal in women (% yes)	52	77	95	60
Ethnicity (% White)	94	94	98	95
Tobacco smoking (% current)	5	12	32	12
Prevalent diabetes ^a (%)	1	6	23	7
Treatment for hypertension (% yes)	17	30	50	28
Anthropometrics				
Systolic blood pressure (mmHg)	123 (13)	136 (14)	143 (16)	131 (16)
Diastolic blood pressure (mmHg)	80 (8)	87 (10)	88 (9)	84 (10)
BMI (kg/m ²), M/W	27.0 (3.6)/27.8 (5.1)	28.2 (3.5)/29.0 (4.1)	29.1 (4.1)/31.8 (6.3)	28.3 (3.8)/28.3 (5.2)
Waist circumference (cm), M/W	96.9 (11.5)/90.5 (13.1)	99.9 (9.2)/94.7 (12.2)	103.5 (12.2)/100.8 (13.8)	100.7 (11.2)/91.9 (13.2)
Waist-hip ratio, M/W	0.92 (0.07)/0.84 (0.07)	0.95 (0.06)/0.88 (0.07)	0.97 (0.07)/0.90 (0.07)	0.95 (0.07)/0.85 (0.07)
Total body fat (%), M/W	24 (7)/39 (7)	26 (5)/41 (6)	29 (6)/42 (6)	27 (6)/40 (7)
Laboratory markers				
Fasting glucose (mmol/L)	5.2 (4.9-5.6)	5.5 (5.2-5.9)	5.7 (5.3-6.6)	5.4 (5.0-5.9)
Fasting insulin (IU/L)	8.5 (5.8-12.3)	9.9 (6.3-14.4)	12.4 (9.0-18.2)	9.6 (6.2-14.3)
HbA _{1c} (%)	5.31 (0.33)	5.42 (0.50)	5.69 (0.87)	5.42 (0.55)
Total cholesterol (mmol/L)	5.64 (1.00)	5.92 (1.12)	6.00 (1.07)	5.80 (1.06)
Triglycerides (mmol/L)	0.84 (0.63-1.21)	1.20 (0.82-1.65)	1.36 (0.98-1.98)	1.05 (0.73-1.48)
HDL cholesterol (mmol/L)	1.67 (0.44)	1.42 (0.38)	1.25 (0.31)	1.51 (0.43)
hsCRP (mg/L)	1.32 (0.7-3.10)	1.31 (0.73-2.92)	1.66 (0.88-3.55)	1.37 (0.73-3.06)
eGFR CKD-EPI (mL/min/1.73 m ²)	87 (12)	86 (12)	84 (12)	86 (12)
Albumin/creatinine ratio (mg/mmol)	0.43 (0.26-0.69)	0.41 (0.26-0.60)	0.43 (0.30-0.71)	0.42 (0.27-0.68)
Microvascular parameters				
Capillary blood volume (pL/mm ²)	2.74 (1.41-4.87)	2.41 (1.43-4.24)	2.21 (1.36-3.52)	2.52 (1.40-4.31)
Capillary density (μm/mm ²)	40 (25-59)	36 (25-57)	33 (24-47)	37 (25-55)
RBC velocity in feed vessels (μm/s)	53 (18)	60 (19)	62 (17)	57 (18)
RBC velocity in capillaries (μm/s)	54 (20)	60 (21)	62 (18)	57 (20)
PBR _{static} (μm)	2.37 (0.24)	2.32 (0.23)	2.31 (0.23)	2.34 (0.24)
PBR _{dynamic} (μm)	2.54 (0.24)	2.57 (0.22)	2.53 (0.22)	2.55 (0.23)

Data are presented as mean (SD), median (25th-75th percentile), or percentage. Framingham Risk Score groups: low risk: <10%; intermediate risk: 10%-20%; high risk: >20%. Missing: 12 HbA_{1c}, 3 eGFR CKD-EPI, and 3 albumin/creatinine ratio.

Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula; eGFR, estimated glomerular filtration rate; HbA_{1c}, hemoglobin A_{1c}; HDL, high-density-lipoprotein; hsCRP, high-sensitivity C-reactive protein; M, men; PBR, perfused boundary region; pL, picoliter; RBC, red blood cell; SDF, sidestream dark field; W, women.

^aSelf-reported diabetes mellitus I or II, medication use, or fasting plasma glucose >7.0 mmol/L.

Statistical analysis

The Framingham Risk Score was calculated by using the Stata module of A. Linden, installed with the syntax “ssc install framingham.” The resulting participants were divided into absolute risk percentage groups classified as low risk (<10%), intermediate risk (10%-20%), or

high (>20%) risk. Data are presented as mean (SD), median (25th-75th percentile), or percentage. Differences in microvascular parameters between the risk groups were analyzed by ANOVA. Capillary blood volume and perfused capillary density we transformed into the natural logarithm. The percentage change of capillary density compared with the low-risk group (reference) was calculated within the capillary

diameters class. The previously mentioned analyses were performed with Stata software (version 14.1; StataCorp, College Station, Texas).

RESULTS

For stratifying the participants ($n = 918$) by Framingham Risk Score, participants with preexisting CVD ($n = 60$) were excluded for this analysis, as were participants with missing data on diabetes status

($n = 5$), systolic blood pressure ($n = 2$), $PBR_{4-25\mu m}$ ($n = 30$), and RBC velocity measurements ($n = 8$). This resulted in a total of 813 participants (382 men and 431 women) included in the present analysis. For each participant, the Framingham Risk Score was calculated, and individuals were divided into risk groups reported as low, intermediate, or high 10-year predicted risk of CVD. Study characteristics and microvascular parameters derived from SDF imaging stratified by Framingham Risk Score groups and in the total cohort are shown in Table 1 and Figure 1. For the statistical analysis,




FIGURE 1 Sidestream dark field imaging–derived parameters of the study population stratified by Framingham Risk Score group. Log-transformed (A) capillary blood volume (B) and capillary density, (C) feed vessel red blood cell (RBC) velocity, (D) capillary RBC velocity, (E) static perfused boundary region (PBR), and (F) dynamic PBR in the low, intermediate, and high Framingham Risk Score groups. Differences in microvascular parameters among the risk groups were analyzed by ANOVA

capillary blood volume and capillary density were log transformed. After log transformation, capillary blood volume was 0.085 (95% CI: 0.003-0.166; Figure 1A) lower in the high-risk group compared with the low-risk group, and the capillary density was 0.063 (95% CI: 0.006-0.121; Figure 1B) lower in the high-risk group compared with the low-risk group. This reduced number of perfused capillary density in the high-risk group was accompanied by increased RBC velocity in the feed vessels and capillaries. Compared with the low-risk group, RBC velocity in the feed vessels was higher in the intermediate-risk group (difference 7.0 $\mu\text{m/s}$ [95% CI: 3.7 to 10.4], Figure 1C) and the high-risk group (difference 9.1 $\mu\text{m/s}$ [95% CI: 5.2 to 12.9], Figure 1C). This higher RBC velocity was also observed within capillaries, with an increase of 6.1 $\mu\text{m/s}$ (95% CI: 2.4 to 9.8) in the intermediate-risk group and an increase of 8.1 $\mu\text{m/s}$ (95% CI: 3.8 to 6.6) in the high-risk group, compared with the low-risk group (Figure 1D). The PBR static was lower in the intermediate-risk group compared with the low-risk group (difference $-0.06 \mu\text{m}$ [95% CI: -0.10 to -0.01], Figure 1E) and in the high-risk group compared with the low-risk group (difference of $-0.06 \mu\text{m}$ [95% CI: -0.12 to -0.01], Figure 1E). However, velocity-corrected PBR (PBR dynamic), based on per-group analysis (9), did not differ across the Framingham Risk Score groups (Figure 1F).

An in-depth analysis of perfused capillary density loss is shown in Figure 2. Capillaries were categorized according to their diameter, and percentage change in capillary density in intermediate- and high-risk groups compared with the low-risk group was calculated. The number of capillaries with a diameter of 4 μm was 49% lower in the high-risk group and 29% lower in the intermediate-risk group. Similarly, densities of 5- μm capillaries were 23% and 10% lower in the high- and the intermediate-risk groups, respectively.

DISCUSSION

In the current study, we observed moderate microvascular differences detected with SDF imaging in individuals with obesity at risk of developing CVD. The number of the smallest functional perfused




FIGURE 2 Percentage difference in the number of perfused capillaries (capillary density) per capillary diameter group in the intermediate- and high-risk Framingham groups compared with the low-risk group (reference)

capillaries (4-6 μm) in individuals with a high risk for developing CVD was reduced, coinciding with moderately lower perfused capillary density and capillary blood volume in the intermediate- and high-risk groups. RBC velocity at intermediate and high risk was higher in both feed vessels ($>10 \mu\text{m}$) and capillaries, possibly because of higher metabolic demand in tissues (10). The loss of functional capillaries in hypertensive or diabetic patients has been a consistent observation over the years (11-13). However, in our current study, we cannot distinguish between capillary rarefaction or reduced nitric oxide production owing to endothelial dysfunction that could lead to impaired vasodilatation and perfusion.

Although the estimated PBR (4-25 μm) seemed to differ among the risk groups, the difference was abolished when PBR was corrected for RBC velocity. In previous studies, PBR was shown to discriminate between specific patient groups and controls (14,15). Interestingly, there is an inconsistency in the range of the measured PBR values in healthy individuals across these studies and our current study. This intravariability across various studies possibly reflects the interindividual variability due to the different flow stages within one person at the time of the SDF measurement, especially in healthy persons. By correcting the PBR for these velocity changes, the new PBR (dynamic) will represent a better estimate of changes in the endothelial glycocalyx layer, as also observed between sepsis patients and healthy controls (9).

A limitation of the current study is that only one SDF measurement per individual was performed. To capture different flow states of the feed vessels and capillaries, new recording and analysis strategies have to be developed to calculate microvascular changes on a per-patient basis. Another limitation is the cross-sectional design of the study. In the current study, minor differences between the cardiovascular risk groups could be detected, with a considerable overlap between the groups. It would be interesting to investigate whether high-risk individuals with microvascular changes develop CVD in the future. A strength of the current study is the large number of participants in the cohort.

In conclusion, we observed that, with adding RBC velocity to the software tool, SDF imaging was able to detect differences within the microvasculature in a cohort of individuals with obesity stratified by CVD risk profile. **O**

CONFLICT OF INTEREST

HV is Chief Science Officer at GlycoCheck BV (Maastricht, The Netherlands). The other authors have nothing to disclose.

AUTHOR CONTRIBUTIONS

JvdV and TJR generated funding. AIMvdV, RdM, and BMvdB were involved in the design of the study. AIMvdV and HV processed data. AIMvdV analyzed the data. All authors were involved in data interpretation and writing of the paper and had final approval of the submitted and published versions.

CLINICAL TRIAL REGISTRATION

ClinicalTrials.gov identifier NCT03410316.

ORCID

B. M. van den Berg  <https://orcid.org/0000-0001-7199-6026>

REFERENCES

1. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. *Circulation*. 2001;104(2):191-196.
2. Halcox JPJ, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. *Circulation*. 2002;106(6):653-658.
3. van den Berg BM, Wang G, Boels MGS, et al. Glomerular function and structural integrity depend on hyaluronan synthesis by glomerular endothelium. *J Am Soc Nephrol*. 2019;30(10):1886-1897.
4. Wang G, Tiemeier GL, van den Berg BM, et al. Endothelial glycocalyx hyaluronan: regulation and role in prevention of diabetic complications. *Am J Pathol*. 2020;190(4):781-790.
5. Lee DH, Dane MJC, van den Berg BM, et al. Deeper penetration of erythrocytes into the endothelial glycocalyx is associated with impaired microvascular perfusion. *PLoS One*. 2014;9(5):e96477. doi:10.1371/journal.pone.0096477
6. Eriksson S, Nilsson J, Stureson C. Non-invasive imaging of microcirculation: a technology review. *Med Devices (Auckl)*. 2014;7:445-452.
7. de Mutsert R, den Heijer M, Rabelink TJ, et al. The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. *Eur J Epidemiol*. 2013;28(6):513-523.
8. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117(6):743-753.
9. Rovas A, Sackarnd J, Rossaint J, et al. Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study. *Crit Care*. 2021;25(1):112.
10. Segal SS. Regulation of blood flow in the microcirculation. *Microcirculation*. 2005;12(1):33-45.
11. de Jongh RT, Serné EH, IJzerman RG, de Vries G, Stehouwer CDA. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. *Circulation*. 2004;109(21):2529-2535.
12. Debbabi H, Uzan L, Mourad J, et al. Increased skin capillary density in treated essential hypertensive patients. *Am J Hypertens*. 2006;19(5):477-483.
13. Mårin P, Andersson B, Krotkiewski M, Björntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. *Diabetes Care*. 1994;17(5):382-386.
14. Dane MJC, Khairoun M, Lee DH, et al. Association of kidney function with changes in the endothelial surface layer. *Clin J Am Soc Nephrol*. 2014;9(4):698-704.
15. Ikonomidis I, Voumvourakis A, Makavos G, et al. Association of impaired endothelial glycocalyx with arterial stiffness, coronary microcirculatory dysfunction, and abnormal myocardial deformation in untreated hypertensives. *J Clin Hypertens (Greenwich)*. 2018;20(4):672-679.

How to cite this article: van der Velden AI, van den Berg BM, de Mutsert R, et al. Microvascular Differences in Individuals With Obesity At Risk of Developing Cardiovascular Disease. *Obesity (Silver Spring)*. 2021;00:1-6. <https://doi.org/10.1002/oby.23222>